AZ-LIMELIGHT-NETWORKS
11.3.2020 12:02:08 CET | Business Wire | Press release
Across the globe people are binge-gaming longer than ever, increasing seven percent from 2019 to an average of four hours and 36 minutes. That’s according to the latest “State of Online Gaming” research report on worldwide consumers’ gaming behaviors and expectations from Limelight Networks Inc., (Nasdaq: LLNW), a leading provider of edge cloud services.
The rise of binge-gaming is an even bigger trend among young gamers. This report showed global respondents ages 18 to 25 binge-play for an average of six hours and 34 minutes, 11 percent longer than one year ago. Japan has the longest average binge-gaming time at more than five and a half hours, and nearly one in ten (9 percent) say they’ve played for more than 15 hours at a time.
While the report shows gamers worldwide spend less time playing video games each week than last year -- averaging six hours and 20 minutes-- their longer binge-gaming sessions can be attributed in part to the rise of anywhere, anytime gaming. Mobile phones are the primary gaming device for worldwide gamers with the preference for smartphone gaming increasing 13 percent from 2019. In addition, this year’s report identified strong interest in console-less gaming services with 44 percent of respondents saying they’re interested in subscribing. Demand for console-less gaming is highest in India where 83 percent of gamers express interest in these services.
Additional insights from the report include:
- Price and performance could limit adoption of console-less gaming. Interest in new console-less gaming platforms is especially high among those who define themselves as experts (71 percent), and among aspiring professional gamers (77 percent). However, concerns with high price points (57 percent) and performance issues such as latency (20 percent) are cited as the top reasons they wouldn’t subscribe. Price sensitivities are highest in the United States (67 percent) and performance concerns are highest in India (28 percent).
- Watching others play video games increased in popularity for younger gamers, sparking the desire to go pro. Gamers ages 18 to 25 watch others play video games online (via platforms such as Twitch or YouTube Gaming) for more than four hours each week and are the most likely to want to turn this hobby into a profession (53 percent).
- Gamers prioritize playing over many daily activities. More than half of gamers (55 percent) have missed sleep to keep playing. Singaporeans are the most likely to choose playing video games over sleeping (60 percent). Many consumers have also skipped meals (32 percent) and showers (22 percent). Younger gamers are the most likely to miss a meal (39 percent) or shower (35 percent) to continue playing.
- Download speed is a top frustration especially for hardcore gamers. The vast majority of global gamers (87 percent) find the process of downloading games frustrating. One-third (32 percent) note slow download speed is their primary concern. Frustrations with download speed are the highest with expert gamers (41 percent) and aspiring professionals (58 percent).
“Players are excited about the flexibility of console-less gaming,” said Michael Milligan, Senior Director at Limelight Networks. “As the world of gaming is being redefined, wide adoption depends on low latency solutions that eliminate frustrating performance disruptions and delays. Keeping gamers engaged requires innovative technology that powers real-time, interactive gaming at the edge.”
The State of Online Gaming report is based on responses from 4,500 consumers in France, Germany, India, Italy, Japan, Singapore, South Korea, the United Kingdom, and the United States age 18 and older who play video games at least once a week. The full report is available here .
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit www.limelight.com
, follow us on Twitter
, Facebook
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom